Source link : https://www.newshealth.biz/health-news/oral-serd-impresses-in-advanced-breast-cancer-with-esr1-mutations/
SAN ANTONIO — Among patients with estrogen receptor (ER)-positive, HER2-negative advanced breast cancer, treatment with imlunestrant did not significantly improve progression-free survival (PFS) compared with standard endocrine therapy, except in those with ESR1 mutations, the phase III EMBER-3 trial showed. Among 256 patients with these mutations, the median PFS was 5.5 months with imlunestrant and […]
Author : News Health
Publish date : 2024-12-11 21:19:06
Copyright for syndicated content belongs to the linked Source.
Categories